Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 16 Feb 2024

Wei Daoyan, Wang Liang, Zuo Xiangsheng, Maitra Anirban, Bresalier Robert S

Abstract excerpt

KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations, with G12D (∼42% of cases) and G12V (∼32% of cases) being the most common. The recent approval of sotorasib (AMG510), a small-molecule, covalent, and selective KRASG12C inhibitor, for treating patients with non-small cell lung cancer represents a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Naphthalenes

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37831007
DOI: 10.1158/1078-0432.CCR-23-2098
PMCID: PMC10922474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.PMID 37831007Read ↗

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity Read ↗

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.Semantic proximity Read ↗

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

MRTX1133 is a potent non-covalent KRAS (G12C) inhibitor with tissue-specific activitySemantic proximity Read ↗

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

Emerging Therapeutic Landscapes for KRAS-Mutant Pancreatic Ductal Adenocarcinoma: Beyond the "Undruggable" Paradigm.Semantic proximity Read ↗

KRAS inhibitors: going noncovalent.Semantic proximity Read ↗

KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.